×

FDA clears clinical trials for Lynk’s oral MS therapy

Lynk Pharmaceuticals has received the green light from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its investigational oral therapy LNK01006, which is being developed for multiple sclerosis (MS) and other neuroinflammatory diseases. “We look forward to advancing this promising molecule…

Cladribine to the rescue of the Gut

Tweet Co-morbidities are a feature of age..as you get older you slowly get all sorts of other conditions….I once went to some student presentations were students have to present on current and future treatments for a condition they had selected autoimmune hepatitis because their mother…

Let’s talk about sleep

It’s been a minute since I’ve had the inclination to write anything. That probably has a lot to do with the fact that I haven’t really slept in several days creating the perfect storm of suck for me both mentally and physically. Not sleeping is in…

How the spoon theory makes communicating MS fatigue easier

I was introduced to the spoon theory not long ago in a graduate school class. The spoon theory, created by lupus patient Christine Miserandino, utilizes a kitchen utensil to illustrate the energy budget of a person living with a disability or chronic illness, which helps…

Finding Balance: Navigating the Holiday Season with MS

For many people, the holidays are pictured as a “most wonderful time of the year,” filled with parties, gifts, and endless cheer. But for those living with multiple sclerosis (MS), the season often feels different. It can bring a complicated … Continue reading → Source:…

Mediterranean and MIND diets track with cognitive benefits in MS

Adherence to either the Mediterranean or the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets was associated with better performance in certain areas of thinking and memory among people with multiple sclerosis (MS), a U.K. study suggests. The Mediterranean diet reflects foods traditionally eaten in countries…

The cost of ADA

Tweet Jamieson T, Tomini F, Gnanapavan S, Mihaylova B. Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study. Eur J Health Econ. 2025 Nov 12. doi: 10.1007/s10198-025-01854-8 Biologic therapies are increasingly used in multiple sclerosis…